Unlike traditional chemotherapy and targeted therapies, which directly attack cancer cells often with significant toxicity, PD-1/PD-L1 inhibitors offer a more targeted approach, potentially leading to better tolerability and prolonged disease control. The gene discussed is CD274; the disease is cancer.